![](https://endpts.com/wp-content/uploads/2021/05/Jason-Kelly-Ginkgo-Bioworks-Getty-tile-scaled.jpg)
Jason Kelly, Ginkgo Bioworks CEO (Kyle Grillot/Bloomberg via Getty Images)
A short-sell attack sends Ginkgo's share price spinning, underscoring investors' concerns over synbio field
Ginkgo Bioworks, a synthetic biology unicorn that has captured investors’ imaginations and trades under Genentech’s hallowed old $DNA ticker, took a big blow Wednesday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.